MYGN position history
The shares of Myriad Genetics (MYGN) that GLENVIEW CAPITAL MANAGEMENT, LLC reported in each quarter’s 13F.
Shares held by quarter
New Add Reduce Exit
- 2021 Q3: 2,235,168 shares, $72M, 1.3% of portfolio
- 2021 Q4: 1,679,747 shares, $46M, 0.99% of portfolio, Reduce −24.8%
- 2022 Q1: 1,737,009 shares, $44M, 0.89% of portfolio, Add +3.4%
- 2022 Q2: 1,696,791 shares, $31M, 0.77% of portfolio, Reduce −2.3%
- 2022 Q3: 1,461,484 shares, $28M, 0.70% of portfolio, Reduce −13.9%
- 2022 Q4: 3,097,768 shares, $45M, 1.00% of portfolio, Add +112.0%
- 2023 Q1: 4,195,112 shares, $97M, 2.1% of portfolio, Add +35.4%
- 2023 Q2: 3,744,888 shares, $87M, 2.0% of portfolio, Reduce −10.7%
- 2023 Q3: 3,783,982 shares, $61M, 1.4% of portfolio, Add +1.0%
- 2023 Q4: 5,283,982 shares, $101M, 2.2% of portfolio, Add +39.6%
- 2024 Q1: 4,943,595 shares, $105M, 1.8% of portfolio, Reduce −6.4%
- 2024 Q2: 3,748,432 shares, $92M, 1.8% of portfolio, Reduce −24.2%
- 2024 Q3: 1,261,530 shares, $35M, 0.67% of portfolio, Reduce −66.3%
- 2024 Q4: 4,157,324 shares, $57M, 1.4% of portfolio, Add +229.5%
- 2025 Q1: 3,899,550 shares, $35M, 0.85% of portfolio, Reduce −6.2%
- 2025 Q2: 4,587,407 shares, $24M, 0.68% of portfolio, Add +17.6%
- 2025 Q3: 4,587,407 shares, $33M, 0.74% of portfolio
- 2025 Q4: 4,587,407 shares, $28M, 0.57% of portfolio
- 2026 Q1: 5,411,978 shares, $24M, 0.61% of portfolio, Add +18.0%
- 2026 Q2: not held, Exit
| Holdings date | Value | % of holdings | Shares | Filing date | All 13F holders |
|---|